AstraZeneca posts MITCHELL asthma results; registers AZD6234 Phase 3 SELENE 2

AstraZeneca had six clinical trial registry updates this week, led by results posted from a completed Phase II asthma study.

• Asthma, "MITCHELL" study (NCT06644924): This completed Phase II crossover trial investigated the therapeutic efficacy and safety of inhaled PT007, referred to as AS MDI, compared with placebo MDI and open-label Ventolin Evohaler in male and female participants aged 18 to 65 years with asthma.¹ The study enrolled 118 participants¹ and results were first posted 2026-08-27.
• Obesity/overweight and Type 2 diabetes, AZD6234, "SELENE 2" (NCT07784270): This newly posted Phase III trial is recruiting. Efficacy of AZD6234 will be compared to placebo in percent body weight change from baseline at 68 weeks of treatment^2,3 in participants with Type 2 diabetes and obesity or overweight, with planned enrollment of 1500 participants.
• Obesity/overweight, AZD6234, "SELENE 1" (NCT07784725): This Phase III trial, first posted 2026-08-25, remains recruiting. Efficacy of AZD6234 will be compared to placebo in percent body weight change from baseline at 68 weeks of treatment in participants without Type 2 diabetes, with planned enrollment of 2500 participants.
• Chronic rhinosinusitis with nasal polyps, tezepelumab (Tezspire), "CREW Study" (NCT07790198): This observational study in Japan is not yet recruiting. It will evaluate mean change from baseline in sinonasal symptoms measured by SNOT-22 total score at 24 weeks from initiation of tezepelumab treatment⁴, with planned enrollment of 100 participants.
• Hepatic impairment, AZD4144 (NCT07783308): This Phase I study is not yet recruiting. It will assess the single oral dose PK, safety, and tolerability of AZD4144 to male and female participants with mild, moderate, and severe hepatic impairment compared to matched controls with normal hepatic function⁵, with up to 30 evaluable participants planned.
• Glomerulonephritis in kidney transplant recipients, China cohort (NCT07783737): This observational study is not yet recruiting. It aims to establish a prospective observational cohort of patients with a confirmed diagnosis of glomerulonephritis (GN) before kidney transplantation in China⁶, enrolling approximately 300 patients across 10 sites.